» Articles » PMID: 23578575

Parkinson's Disease Cognitive Network Correlates with Caudate Dopamine

Overview
Journal Neuroimage
Specialty Radiology
Date 2013 Apr 13
PMID 23578575
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Prior evidence has suggested a link between caudate dopaminergic functioning and cognition in Parkinson's disease (PD). In this dual tracer study we analyzed the relationship between nigrostriatal dopaminergic dysfunction and the expression of the previously validated PD cognition-related metabolic pattern (PDCP). In this study, 17 non-demented PD patients underwent positron emission tomography (PET) imaging with [(18)F]-fluorodeoxyglucose to measure PDCP expression, and [(18)F]-fluoropropyl-β-CIT (FPCIT) to measure dopamine transporter (DAT) binding. Automated voxel-by-voxel searches of the FPCIT PET volumes were performed to identify regions in which DAT binding significantly correlated with PDCP expression values. The findings were validated using prespecified anatomical regions-of-interest (ROIs). Voxel-wise interrogation of the FPCIT PET scans revealed a single significant cluster in which DAT binding correlated with PDCP expression (p<0.05, corrected). This cluster was localized to the left caudate nucleus; an analogous correlation (r=-0.63, p<0.01) was also present in the "mirror" region of the right hemisphere. These findings were confirmed by the presence of a significant correlation (r=-0.67, p<0.005) between PDCP expression and DAT binding in caudate ROIs, which survived adjustment for age, disease duration, and clinical severity ratings. Correlation between caudate DAT binding and subject expression of the PD motor-related metabolic pattern was not significant (p>0.21). In summary, this study demonstrates a significant relationship between loss of dopaminergic input to the caudate nucleus and the expression of a cognition-related disease network in unmedicated PD patients. These baseline measures likely function in concert to determine the cognitive effects of dopaminergic therapy in PD.

Citing Articles

Striatal dopamine transporter uptake predicts neuronal hypometabolism and visuospatial function in Parkinson's disease.

Seo S, Yoon Y, Lee S, Lim H, Choo K, Kim D Eur J Nucl Med Mol Imaging. 2025; .

PMID: 39951136 DOI: 10.1007/s00259-025-07137-x.


Neural substrates underlying distinct dual cognitive syndromes in Parkinson's disease.

Yoshimura K, Shima A, Kambe D, Furukawa K, Nishida A, Wada I Eur J Neurol. 2024; 32(1):e70022.

PMID: 39716907 PMC: 11666957. DOI: 10.1111/ene.70022.


Imaging Procedure and Clinical Studies of [F]FP-CIT PET.

Sung C, Oh S, Kim J Nucl Med Mol Imaging. 2024; 58(4):185-202.

PMID: 38932763 PMC: 11196481. DOI: 10.1007/s13139-024-00840-x.


Metabolic network alterations as a supportive biomarker in dementia with Lewy bodies with preserved dopamine transmission.

Stockbauer A, Beyer L, Huber M, Kreuzer A, Palleis C, Katzdobler S Eur J Nucl Med Mol Imaging. 2023; 51(4):1023-1034.

PMID: 37971501 PMC: 10881642. DOI: 10.1007/s00259-023-06493-w.


Quantitative dopamine transporter imaging assessment in Parkinson's disease patients carrying GBA gene mutations compared with idiopathic PD patients: A case-control study.

Grisanti S, Fraternali A, Cavallieri F, Fioravanti V, Casali M, Toschi G Brain Behav. 2023; 13(7):e3060.

PMID: 37264751 PMC: 10338803. DOI: 10.1002/brb3.3060.


References
1.
Carbon M, Ma Y, Barnes A, Dhawan V, Chaly T, Ghilardi M . Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism. Neuroimage. 2004; 21(4):1497-507. DOI: 10.1016/j.neuroimage.2003.12.014. View

2.
Jacobson N, Truax P . Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol. 1991; 59(1):12-9. DOI: 10.1037//0022-006x.59.1.12. View

3.
Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D . Metabolic brain networks associated with cognitive function in Parkinson's disease. Neuroimage. 2006; 34(2):714-23. PMC: 4456012. DOI: 10.1016/j.neuroimage.2006.09.003. View

4.
Tang C, Poston K, Dhawan V, Eidelberg D . Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease. J Neurosci. 2010; 30(3):1049-56. PMC: 2866050. DOI: 10.1523/JNEUROSCI.4188-09.2010. View

5.
Braak H, Del Tredici K, Rub U, de Vos R, Jansen Steur E, Braak E . Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2002; 24(2):197-211. DOI: 10.1016/s0197-4580(02)00065-9. View